• My research interests have always been centered on glioblastoma (GBM) tumors, a particularly devastating brain tumor. My current research interests are centered around discovering new therapies for patients with GBM, which include pharmacological inhibition of the JAK/STAT pathway in patient-derived xenograft models, exploiting inflammatory (anti-tumor) macrophages to enhance standard of care in immunocompetent models, and understanding how the gut microbiome is altered by the diet as well as by certain drug therapies in mouse models of glioma.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2017 Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells.Journal of Neuro-Oncology.  132:219-229. 2017
    2016 Attenuation of PKR-like ER Kinase (PERK) Signaling Selectively Controls Endoplasmic Reticulum Stress-induced Inflammation Without Compromising Immunological Responses.Journal of Biological Chemistry.  291:15830-15840. 2016
    2016 Loss of SOCS3 in myeloid cells prolongs survival in a syngeneic model of glioma.Oncotarget.  7:20621-20635. 2016
    2015 Loss of tumor suppressive microRNA-31 enhances TRADD/NF-κB signaling in glioblastoma.Oncotarget.  6:17805-17816. 2015
    2015 SOCS3 Deficiency in Myeloid Cells Promotes Tumor Development: Involvement of STAT3 Activation and Myeloid-Derived Suppressor Cells.Cancer Immunology Research.  3:727-740. 2015
    2014 NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age.Expert Review of Neurotherapeutics.  14:1293-1306. 2014
    2014 Therapeutic CK2 inhibition attenuates diverse prosurvival signaling cascades and decreases cell viability in human breast cancer cells.Oncotarget.  5:6484-6496. 2014
    2014 Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis.Journal of Interferon and Cytokine Research.  34:577-588. 2014
    2014 Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis.Journal of Immunology.  192:59-72. 2014
    2013 Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.Clinical Cancer Research.  19:6484-6494. 2013
    2013 Activation of the NF-κB pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells.Cell Growth and Differentiation.  11:494-505. 2013
    2013 NF-κB-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma.PLoS ONE.  8:e78728. 2013
    2011 Therapeutic potential of AZD1480 for the treatment of human glioblastoma.Molecular Cancer Therapeutics.  10:2384-2393. 2011
    2009 Plasminogen kringle 5 induces apoptosis of brain microvessel endothelial cells: sensitization by radiation and requirement for GRP78 and LRP1.Cancer Research.  69:5537-5545. 2009
    2008 New molecular targets in angiogenic vessels of glioblastoma tumours.Expert Reviews in Molecular Medicine.  10:e23. 2008
    2007 Erratum: HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells (Oncogene (2006) 25, (1721-1732) DOI: 10.1038/sj.onc.1209199)Oncogene.  26:7282. 2007
    2006 New concepts regarding focal adhesion kinase promotion of cell migration and proliferation.Journal of Cellular Biochemistry.  99:35-52. 2006
    2006 HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells.Oncogene.  25:1721-1732. 2006


    Year Title Altmetric
    2015 Protein kinase CK2 and dysregulated oncogenic inflammatory signaling pathways.  259-280. 2015

    Full Name

  • Braden McFarland